Distribution of FAM-tagged or Cy7-tagged APIM-peptide (9/10 mg net APIM peptide/kg BW in saline) in different organs harvested immediately after i.v. infusion (4 mL/h, 30 min). Frozen sections of thigh muscle, heart, kidney, brain, liver and bladder were DNA-stained with DAPI and evaluated by confocal microscopy using a 20x dry objective. Organs harvested from vehicle treated rats were used as controls. Table of relative metabolite levels between treatments in both cell lines. The average of four independent cultures is presented for each of three biological replicas. (C) Simplified schematic overview of central carbon metabolism covered by targeted metabolic profiling. Levels of significantly changed glycolytic, TCA and PPP intermediates, phosphorylated sugars, amino acids and (deoxy)nucleoside phosphates and consumption/production of glucose, glutamine and lactate in combination treated cell/24h relative to control in T-24 cells (ANOVA and post hoc Tukey's range test, p<0.05). The average of four independent cultures from one representative biological replica is presented. Bold metabolites: Reproduced in Um-Uc-3 cells, "+"-denoted metabolites: metabolite level was more (>10%) affected by combination treatment than by cisplatin single-agent treatment.
Supplementary Figure 5:
Cisplatin induce S-phase arrest in Um-Uc-3 and Um-Uc-3-R cells, while apoptosis only is induced in Um-Uc-3 cells at 24h. Analysis of Um-Uc-3 (black) and Um-Uc-3-R (grey) cells treated for 24h with APIM-peptide (8 µM) and cisplatin (10 µM) alone or in combination. (A) Flow cytometry cell cycle analysis performed as previously described (Søgaard et al, Oncotarget, 2018) . The average percentage cells in each cell cycle phase ± SD (n=3) are presented in the bar graph, with representative cell cycle distribution graphs on top. (B) Average percentage apoptotic cells ± SEM (n=6). * p<0.05, ** p>0.01 (student-t test, two tailed) measured by flow cytometry as described (Søgaard et al, Oncotarget, 2018) . (C) Average viability ± SEM (n=3) of treated cell relative to untreated cells analyzed with the MTT-assay.
